Ajanta Net Income From Continuing Ops from 2010 to 2024
| AJANTPHARM | 2,960 14.55 0.49% |
Net Income From Continuing Ops | First Reported 2017-03-31 | Previous Quarter 2 B | Current Value 2.5 B | Quarterly Volatility 430.6 M |
Check Ajanta Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ajanta Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 83.5 M or Selling And Marketing Expenses of 42.7 M, as well as many indicators such as . Ajanta financial statements analysis is a perfect complement when working with Ajanta Pharma Valuation or Volatility modules.
Ajanta | Net Income From Continuing Ops |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ajanta Stock
Ajanta Pharma financial ratios help investors to determine whether Ajanta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ajanta with respect to the benefits of owning Ajanta Pharma security.